Medical Innovation for Enhanced Patient Care

Founded in 2018, Avicenna.AI was formed through a collaboration between Cyril Di Grandi, a software and medical device expert and Peter Chang, MD, a radiologist and AI expert.

We develop AI-based solutions for radiology that provide healthcare professionals with the ability to accelerate the therapeutic decision-making process and improve patient outcomes.

Play Video about avicenna.AI 1920 × 1080
partners
Distributors
0 +
hospitals
Hospitals
0 +
mapa mundi
Countries
0 +

Our Journey Throught Innovation

2018
June
Inception
Avicenna.AI is born

Founded in June 2018, Avicenna.AI was formed through a collaboration between Cyril Di Grandi, a software and medical device expert and Peter Chang, MD, a radiologist and AI expert.

2019
September
Fundraising
Avicennai.AI first fundraising

Avicenna.AI secured its initial capital infusion of $2.7 million through investments from the French companies Innovacom and CEMAG Invest.

2020
Product Launch
CINA, a suite of AI tools for Stroke

Avicenna.AI introduced its first products, CINA-ICH and CINA-LVO, triage tools for stroke detection. Both solutions obtained the CE-marking in March, swiftly followed by FDA clearance in June.

December
Product Launch
CINA Chest for thoraco-abdominal pathologies

Avicenna.AI introduced CINA-PE and CINA-AD, two solutions designed for Pulmonary Embolism and Aortic Dissection detection. These innovations achieved CE-marking in December.

2021
May
Product Launch
FDA clearance and Launch of CINA-ASPECTS

In May 2021, Avicenna.AI successfully obtained FDA clearance for CINA-PE and CINA-AD, while also launching and securing the CE marking for its new Stroke quantification tool, CINA-ASPECTS.

2022
December
Fundraising
Avicenna.AI Serie A fundraising

Avicenna.AI secured a Series A funding round, bringing aggregated investment close to $10 million. The round was backed by existing investors Innovacom and CEMAG Invest.

2023
March
Product Launch
Introduction of the Incidental Suite

Avicenna.AI introduced its new Incidental findings Suite, with the launch of CINA-iPE for unsuspected Pulmonary Embolism detection.

2024
March
Product Launch
FDA-Clearance for CINA-ASPECTS and CINA-iPE

Avicenna.AI Secures Two FDA Clearances For Stroke Assessment And Opportunistic Pulmonary Embolism.

Our Solutions

Head

Solutions for neurovascular pathologies

Chest

Solutions for thoraco-abdominal pathologies

Our Core Values

Excellence

The characteristics and quality of our products reflect the excellence of our team, and we work with determination and rigour to provide our partners with increasingly efficient solutions.

Learning

We use the power of deep learning to create AI solutions. But learning is also fundamental to how we operate as a company, and we continually seek to challenge ourselves and innovate.

Expertise

Throughout our business, we bring together the experts that can make a difference – from specialists in machine learning and software development to leaders in radiology and clinical practice.

Collaboration

We value sharing and fairness, guiding our product development to provide effective solutions to our customers, while actively prioritizing collaborative teamwork to achieve our common goals.

Innovation

Innovation drives us to explore new avenues for delivering superior solutions to our customers, making it a central and invigorating challenge within our company as we continually seek to surpass expectations.

Meet Our Team

The company has built a team of experienced professionals from multiple domains of expertise who believe in the power of new technology to meet today’s clinical needs. 

[zcwp id = 3]